IFNα-derived therapies are the only approved adjuvant therapies in melanoma patients after surgical resection, and immunomodulatory actions, such as increased tumor-infiltrating cells and decreased circulating T-regulatory cells, are key mechanisms of action [reviewed in reference (242)]. This evidence concerns the gene IFNA1 and melanoma.